A newly-formed investment management business, Carrara Investment Management manages Australian equities via the company Concentrated Leaders Fund, with plans to build a broader business in global equities, trading and credit over the coming years.
A publicly-listed biopharmaceutical company with three clinically advanced products in development, XORTX Therapeutics’ focus is on developing drugs for kidney disease treatment, an area where there is a large unmet medical need for therapeutics.
Boardroom Broadcasts provides in-depth interviews with businesses looking to increase their visibility internationally. Featuring top executives in front of an audience of other executive leaders including retail & institutional investors from private equity, venture capital, and financial institutions.
All copy appearing in Boardroom Broadcasts is copyrighted. Reproduction in whole or part is not permitted without written permission. Any financial advice published in Boardroom Broadcasts or on BoardroomBroadcasts.com has been prepared without taking into account the objectives, financial situation or needs of any reader. Neither Boardroom Broadcasts nor the publisher nor any of its employees hold any responsibility for any losses and or injury incurred (if any) by acting on information provided. All opinions expressed are held solely by the interviewees and contributors, and are not endorsed by Boardroom Broadcasts or BoardroomBroadcasts.com.
All reasonable care is taken to ensure truth and accuracy, but neither the editor nor the publisher can be held responsible for errors or omissions in articles, advertising, photographs or illustrations. Unsolicited manuscripts are welcome but cannot be returned without a stamped, self-addressed envelope. The publisher is not responsible for material submitted for consideration.